Circulating Advanced Oxidation Protein Products (AOPPs) increases the risk of metabolic syndrome among adults: A systematic review and meta-analysis

Abstract

BackgroundSeveral studies have highlighted the possible role of advanced oxidation protein products (AOPPs) in promotion of metabolic syndrome (MetS). However, due to inconsistencies in this field, we aimed to quantitatively summarize the results of studies that evaluated the association between AOPPs, with MetS indices among adult population.MethodsIn a systematic search from PubMed, Embase, and Scopus electronic databases until 15 August 2022 without language restriction, a total of 1225 articles were obtained. Finally, after duplicate removal of 632 articles and removing of 537 articles according to title/abstract, seven article was included in final meta-analysis. These articles all had observational design, were performed in adults aged more than 18 years old, and evaluated the association between circulating AOPPs and MetS.ResultsIn our meta-analysis, circulating AOPPs was 17.51 mu mol/L higher in individuals with MetS versus individuals without MetS (WMD: 17.512; CI: 12.084, 22.939; p = 0.001). Gender, age, and sample size were recognized as possible heterogeneity sources in subgrouping and meta-regression. No evidence of publication bias was reported.ConclusionAccording to the results of the current meta-analysis, higher circulating AOPPs concentrations might be associated with MetS risk among adults. Further longitudinal studies are needed to better identify the causal associations between these variables.